Clinical and Molecular Findings in a Turkish Family Who Had a (c.869-
1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant
Alzheimer's Disease with Spastic Paraparesis

Mustafa      Doğan; Recep      Eröz; Mehmet      Tecellioğlu; Alper      Gezdirici; Betül      Çevik; İbrahim      Barış

doi:10.2174/1567205019666220414101251

Abstract

Background: Early-onset Alzheimer's disease (EOAD) is commonly diagnosed with an onset age of earlier than 65 years and accounts for 5–10% of all Alzheimer's disease (AD) cases. To date, although only 10-15% of familial EOAD cases have been explained, the genetic cause of the vast proportion of cases has not been explained. The variant Alzheimer's disease with spastic paraparesis (var- AD) is defined as a rare clinical entity characterized by early-onset dementia, spasticity of the lower extremities, and gait disturbance. Although the disease was first associated with variants in exon 9 of the PSEN1 gene, it was later shown that variations in other exons were also responsible for the disease.

Objective: The current study aims to raise awareness of varAD, which occurs as a rare phenotype due to pathogenic variants in PSEN1. In addition, we aimed to evaluate the spectrum of mutations in varAD patients identified to date.

Methods: Detailed family histories and clinical data were recorded. Whole exome sequencing was performed and co-segregation analysis of the family was done by Sanger sequencing. Also, a review of the molecularly confirmed patients with (varAD) from the literature was evaluated.

Results: We identified a heterozygous splicing variant (c.869-1G>A) in the PSEN1 gene, in a family with two affected individuals who present with varAD. We reported the clinical and genetic findings from the affected individuals.

Conclusion: We present the detailed clinical and genetic profiles of a Turkish patient with the diagnosis of varAD together with subjects from the literature. Together, we think that the clinical characteristics and the effect of the (c.869-1G>A) variant will facilitate our understanding of the PSEN1 gene in AD pathogenesis.

Keywords: Alzheimer's disease, Early-onset, familial, presenilin 1, PSEN1, whole exome sequencing, dementia, neurodegeneration, spastic paraparesis

« Previous Next »

[1] 
Leyhe T, Reynolds CF III, Melcher T, et al. A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimers Dement  2017; 13(1): 59-71.
[http://dx.doi.org/10.1016/j.jalz.2016.08.007] [PMID:  27693188] 
[2] 
Jack CR Jr, Bennett DA, Blennow K, et al. Contributors. NIA-AA Research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement  2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID:  29653606] 
[3] 
Alzheimer’s disease facts and figures. Alzheimers Dement  2021; 17(3): 327-406.
[http://dx.doi.org/10.1002/alz.12328] [PMID:  33756057] 
[4] 
Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol  2012; 69(1): 59-64.
[http://dx.doi.org/10.1001/archneurol.2011.221] [PMID:  21911656] 
[5] 
Tellechea P, Pujol N, Esteve-Belloch P, et al. Early- and late-onset Alzheimer disease: Are they the same entity? Neurologia  2018; 33(4): 244-53.
[http://dx.doi.org/10.1016/j.nrleng.2015.08.009] [PMID:  26546285] 
[6] 
Giau VV, Senanarong V, Bagyinszky E, An SSA, Kim S. Analysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer’s disease. Int J Mol Sci  2019; 20(6): E1514.
[http://dx.doi.org/10.3390/ijms20061514] [PMID:  30917570] 
[7] 
Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-onset Alzheimer’s disease: What is missing in research? Curr Neurol Neurosci Rep  2021; 21(2): 4.
[http://dx.doi.org/10.1007/s11910-020-01090-y] [PMID:  33464407] 
[8] 
Bates KA, Verdile G, Li QX, et al. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: Implications for therapeutic design and diagnostic tests. Mol Psychiatry  2009; 14(5): 469-86.
[http://dx.doi.org/10.1038/mp.2008.96] [PMID:  18794889] 
[9] 
Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer’s disease: Beyond APP, PSENs and APOE. Neurobiol Aging  2012; 33(3): 437-56.
[http://dx.doi.org/10.1016/j.neurobiolaging.2010.03.025] [PMID:  20594621] 
[10] 
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet Med  2016; 18(5): 421-30.
[http://dx.doi.org/10.1038/gim.2015.117] [PMID:  26312828] 
[11] 
Uddin MS, Hasana S, Hossain MF, et al. Molecular genetics of early- and late-onset Alzheimer’s disease. Curr Gene Ther  2021; 21(1): 43-52.
[http://dx.doi.org/10.2174/1566523220666201123112822] [PMID:  33231156] 
[12] 
Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther  2011; 3(1): 1.
[http://dx.doi.org/10.1186/alzrt59] [PMID:  21211070] 
[13] 
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med  2003; 348(14): 1356-64.
[http://dx.doi.org/10.1056/NEJM2003ra020003] [PMID:  12672864] 
[14] 
Escamilla-Ayala A, Wouters R, Sannerud R, Annaert W. Contribution of the Presenilins in the cell biology, structure and function of γ-secretase. Semin Cell Dev Biol  2020; 105: 12-26.
[http://dx.doi.org/10.1016/j.semcdb.2020.02.005] [PMID:  32146031] 
[15] 
Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement  2016; 12(6): 733-48.
[http://dx.doi.org/10.1016/j.jalz.2016.01.012] [PMID:  27016693] 
[16] 
Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol  2014; 88(4): 640-51.
[http://dx.doi.org/10.1016/j.bcp.2013.12.024] [PMID:  24398425] 
[17] 
Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat  2012; 33(9): 1340-4.
[http://dx.doi.org/10.1002/humu.22117] [PMID:  22581678] 
[18] 
Ryman DC, Acosta-Baena N, Aisen PS, et al. Dominantly inherited Alzheimer network. symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology  2014; 83(3): 253-60.
[http://dx.doi.org/10.1212/WNL.0000000000000596] [PMID:  24928124] 
[19] 
Barber IS, Garcia-Cardenas JM, Sakdapanichkul C, et al. Screening
exons 16 and 17 of the amyloid precursor protein gene in sporadic
early-onset Alzheimer's disease. Neurobiol Aging  2016; 39: 220e1-7.
[http://dx.doi.org/10.1016/j.neurobiolaging.2015.12.011] 
[20] 
Golan MP, Styczyńska M, Jóźwiak K, et al Early-onset Alzheimer’s disease with a de novo mutation in the presenilin 1 gene. Exp Neurol  2007; 208(2): 264-8.
[http://dx.doi.org/10.1016/j.expneurol.2007.08.016] [PMID:  17931627] 
[21] 
Lanoiselée HM, Nicolas G, Wallon D, et al. collaborators of the CNR-MAJ project. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med  2017; 14(3): e1002270.
[http://dx.doi.org/10.1371/journal.pmed.1002270] [PMID:  28350801] 
[22] 
Smith MJ, Kwok JB, McLean CA, et al. Variable phenotype of Alzheimer’s disease with spastic paraparesis. Ann Neurol  2001; 49(1): 125-9.
[http://dx.doi.org/10.1002/1531-8249(200101)49:1<125::AIDANA21>3.0.CO;2-1] [PMID:  11198283] 
[23] 
Tabira T, Chui DH, Nakayama H, Kuroda S, Shibuya M. Alzheimer’s disease with spastic paresis and cotton wool type plaques. J Neurosci Res  2002; 70(3): 367-72.
[http://dx.doi.org/10.1002/jnr.10392] [PMID:  12391599] 
[24] 
Jacquemont ML, Campion D, Hahn V, et al. Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer’s disease. J Med Genet  2002; 39(2): E2.
[http://dx.doi.org/10.1136/jmg.39.2.e2] [PMID:  11836371] 
[25] 
O’Riordan S, McMonagle P, Janssen JC, et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology  2002; 59(7): 1108-10.
[http://dx.doi.org/10.1212/WNL.59.7.1108] [PMID:  12370477] 
[26] 
Pettersen JA, Patry DG, St George-Hyslop PH, Curry B. Variant Alzheimer disease with spastic paraparesis: A rare presenilin-1 mutation. Can J Neurol Sci  2011; 38(4): 659-61.
[http://dx.doi.org/10.1017/S0317167100012233] [PMID:  21672709] 
[27] 
Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med  2015; 17(5): 405-24.
[http://dx.doi.org/10.1038/gim.2015.30] [PMID:  25741868] 
[28] 
Perrone F, Bjerke M, Hens E, et al. BELNEU Consortium. Amyloid-β1-43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. Alzheimers Res Ther  2020; 12(1): 108.
[http://dx.doi.org/10.1186/s13195-020-00676-5] [PMID:  32917274] 
[29] 
Molinuevo JL, Blennow K, Dubois B, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement  2014; 10(6): 808-17.
[http://dx.doi.org/10.1016/j.jalz.2014.03.003] [PMID:  25150736] 
[30] 
Brooks WS, Kwok JB, Kril JJ, et al. Alzheimer’s disease with spastic paraparesis and ‘cotton wool’ plaques: Two pedigrees with PS-1 exon 9 deletions. Brain  2003; 126(Pt 4): 783-91.
[http://dx.doi.org/10.1093/brain/awg084] [PMID:  12615638] 
[31] 
Sato S, Kamino K, Miki T, et al. Splicing mutation of presenilin-1 gene for early-onset familial Alzheimer’s disease. Hum Mutat  1998; 11(S1)(Suppl. 1): S91-4.
[http://dx.doi.org/10.1002/humu.1380110131] [PMID:  9452052] 
[32] 
Qiang L, Fujita R, Yamashita T, et al. Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neurons. Cell  2011; 146(3): 359-71.
[http://dx.doi.org/10.1016/j.cell.2011.07.007] [PMID:  21816272] 
[33] 
Le Guennec K, Veugelen S, Quenez O, et al. Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds. Neurobiol Dis  2017; 104: 97-103.
[http://dx.doi.org/10.1016/j.nbd.2017.04.020] [PMID:  28461250] 
[34] 
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science  2002; 297(5580): 353-6.
[http://dx.doi.org/10.1126/science.1072994] [PMID:  12130773] 
[35] 
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med  2016; 8(6): 595-608.
[http://dx.doi.org/10.15252/emmm.201606210] [PMID:  27025652] 
[36] 
Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron  2004; 42(1): 23-36.
[http://dx.doi.org/10.1016/S0896-6273(04)00182-5] [PMID:  15066262] 
[37] 
Wines-Samuelson M, Schulte EC, Smith MJ, et al. Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. PLoS One  2010; 5(4): e10195.
[http://dx.doi.org/10.1371/journal.pone.0010195] [PMID:  20419112] 
[38] 
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat Neurosci  2012; 15(3): 349-57.
[http://dx.doi.org/10.1038/nn.3028] [PMID:  22286176] 
[39] 
Quintero-Monzon O, Martin MM, Fernandez MA, et al. Dissociation between the processivity and total activity of γ-secretase: Implications for the mechanism of Alzheimer’s disease-causing presenilin mutations. Biochemistry  2011; 50(42): 9023-35.
[http://dx.doi.org/10.1021/bi2007146] [PMID:  21919498] 
[40] 
Fiorini M, Bongianni M, Benedetti MD, Monaco S, Zanusso G. Reappraisal of Aβ40 and Aβ42 peptides measurements in cerebrospinal fluid of patients with Alzheimer’s disease. J Alzheimers Dis  2018; 66(1): 219-27.
[http://dx.doi.org/10.3233/JAD-180616] [PMID:  30282368] 
[41] 
Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol  2006; 59(3): 512-9.
[http://dx.doi.org/10.1002/ana.20730] [PMID:  16372280] 
[42] 
Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O. Geneva Task Force for the Roadmap of Alzheimer’s B. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging  2017; 52: 196-213.
[http://dx.doi.org/10.1016/j.neurobiolaging.2016.02.034] [PMID:  28317649] 
[43] 
Bignante EA, Heredia F, Morfini G, Lorenzo A. Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer’s disease. Neurobiol Aging  2013; 34(11): 2525-37.
[http://dx.doi.org/10.1016/j.neurobiolaging.2013.04.021] [PMID:  23714735] 
[44] 
Struyfs H, Van Broeck B, Timmers M, et al. Diagnostic Accuracy of cerebrospinal fluid Amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis  2015; 45(3): 813-22.
[http://dx.doi.org/10.3233/JAD-141986] [PMID:  25633670] 
[45] 
Jongbloed W, Bruggink KA, Kester MI, et al. Amyloid-β oligomers relate to cognitive decline in Alzheimer’s disease. J Alzheimers Dis  2015; 45(1): 35-43.
[http://dx.doi.org/10.3233/JAD-142136] [PMID:  25547634] 
[46] 
Güner G, Lichtenthaler SF. The substrate repertoire of γ-secretase/presenilin. Semin Cell Dev Biol  2020; 105: 27-42.
[http://dx.doi.org/10.1016/j.semcdb.2020.05.019] [PMID:  32616437] 
[47] 
Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s Disease: Causes and treatment. Molecules  2020; 25(24): E5789.
[http://dx.doi.org/10.3390/molecules25245789] [PMID:  33302541] 
[48] 
Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Alzheimer’s Disease Neuroimaging I. Association of CSF Abeta, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology  2020; 95(15): e2075-85.
[http://dx.doi.org/10.1212/WNL.0000000000010596] [PMID:  32759202] 
[49] 
Mastrangelo P, Mathews PM, Chishti MA, et al. Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci USA  2005; 102(25): 8972-7.
[http://dx.doi.org/10.1073/pnas.0500940102] [PMID:  15951428] 
[50] 
Kim YE, Cho H, Kim HJ, Na DL, Seo SW, Ki CS. PSEN1 variants in Korean patients with clinically suspicious early-onset familial Alzheimer’s disease. Sci Rep  2020; 10(1): 3480.
[http://dx.doi.org/10.1038/s41598-020-59829-z] [PMID:  32103039] 
[51] 
Perez-Tur J, Froelich S, Prihar G, et al. A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport  1995; 7(1): 297-301.
[http://dx.doi.org/10.1097/00001756-199512000-00071] [PMID:  8742474] 
[52] 
Steiner H, Romig H, Grim MG, et al. The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem  1999; 274(12): 7615-8.
[http://dx.doi.org/10.1074/jbc.274.12.7615] [PMID:  10075646] 
[53] 
Woodruff G, Young JE, Martinez FJ, et al. The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep  2013; 5(4): 974-85.
[http://dx.doi.org/10.1016/j.celrep.2013.10.018] [PMID:  24239350] 
[54] 
Hiltunen M, Helisalmi S, Mannermaa A, et al. Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer’s disease family: An Alu core sequence-stimulated recombination? Eur J Hum Genet  2000; 8(4): 259-66.
[http://dx.doi.org/10.1038/sj.ejhg.5200423] [PMID:  10854108] 
[55] 
Rovelet-Lecrux A, Charbonnier C, Wallon D, et al. CNR-MAJ collaborators. De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease. Mol Psychiatry  2015; 20(9): 1046-56.
[http://dx.doi.org/10.1038/mp.2015.100] [PMID:  26194182] 
[56] 
Blauwendraat C, Wilke C, Jansen IE, et al. Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variantsNeurobiol
 Aging  2016; 37: 208 e11-7.
[http://dx.doi.org/10.1016/j.neurobiolaging.2015.09.016] 
[57] 
Koriath C, Kenny J, Adamson G, et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol Psychiatry  2020; 25(12): 3399-412.
[http://dx.doi.org/10.1038/s41380-018-0224-0] [PMID:  30279455] 
[58] 
Crook R, Verkkoniemi A, Perez-Tur J, et al. A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med  1998; 4(4): 452-5.
[http://dx.doi.org/10.1038/nm0498-452] [PMID:  9546792] 
[59] 
Kwok JB, Taddei K, Hallupp M, et al. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer’s disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport  1997; 8(6): 1537-42.
[http://dx.doi.org/10.1097/00001756-199704140-00043] [PMID:  9172170] 
[60] 
Houlden H, Baker M, McGowan E, et al. Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol  2000; 48(5): 806-8.
[http://dx.doi.org/10.1002/1531-8249(200011)48:5<806::AIDANA18>3.0.CO;2-F] [PMID:  11079548] 
[61] 
Sodeyama N, Iwata T, Ishikawa K, et al. Very early onset Alzheimer’s disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile). J Neurol Neurosurg Psychiatry  2001; 71(4): 556-7.
[http://dx.doi.org/10.1136/jnnp.71.4.556] [PMID:  11561050] 
[62] 
Moretti P, Lieberman AP, Wilde EA, et al. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology  2004; 62(10): 1865-8.
[http://dx.doi.org/10.1212/01.WNL.0000126447.91111.A1] [PMID:  15159497] 
[63] 
Matsubara-Tsutsui M, Yasuda M, Yamagata H, et al. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am J Med Genet  2002; 114(3): 292-8.
[http://dx.doi.org/10.1002/ajmg.10250] [PMID:  11920851] 
[64] 
Assini A, Terreni L, Borghi R, et al. Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology  2003; 60(1): 150.
[http://dx.doi.org/10.1212/01.WNL.0000040252.43269.83] [PMID:  12525746] 
[65] 
Raman A, Lin X, Suri M, Hewitt M, Constantinescu CS, Phillips MF. A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer’s disease and spastic paraparesis. J Neurol Sci  2007; 260(1-2): 78-82.
[http://dx.doi.org/10.1016/j.jns.2007.04.013] [PMID:  17507029] 
[66] 
Uttner I, Kirchheiner J, Tumani H, et al. A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer’s disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. Eur J Neurol  2010; 17(4): 631-3.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02810.x] [PMID:  19912322] 
[67] 
Kowalska A, Forsell C, Florczak J, et al. A Polish pedigree with Alzheimer’s disease determined by a novel mutation in exon 12 of the presenilin 1 gene: Clinical and molecular characterization. Folia Neuropathol  1999; 37(1): 57-61.
[PMID: 10337065] 
[68] 
Dintchov Traykov L, Mehrabian S, Van den Broeck M, et al. Novel PSEN1 mutation in a Bulgarian patient with very early-onset Alzheimer’s disease, spastic paraparesis, and extrapyramidal signs. Am J Alzheimers Dis Other Demen  2009; 24(5): 404-7.
[http://dx.doi.org/10.1177/1533317509341464] [PMID:  19797784] 
[69] 
Dumanchin C, Tournier I, Martin C, et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum Mutat  2006; 27(10): 1063.
[http://dx.doi.org/10.1002/humu.9458] [PMID:  16941492] 
[70] 
Hattori S, Sakuma K, Wakutani Y, et al. A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer’s disease with spastic paraparesis. Neurosci Lett  2004; 368(3): 319-22.
[http://dx.doi.org/10.1016/j.neulet.2004.07.057] [PMID:  15364419] 
[71] 
Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology  2001; 57(4): 621-5.
[http://dx.doi.org/10.1212/WNL.57.4.621] [PMID:  11524469] 
[72] 
Oksanen M, Hyötyläinen I, Trontti K, et al. NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer’s disease astrocytes. Glia  2020; 68(3): 589-99.
[http://dx.doi.org/10.1002/glia.23741] [PMID:  31670864] 
[73] 
Oikari LE, Pandit R, Stewart R, et al. Altered brain endothelial cell phenotype from a familial Alzheimer mutation and its potential implications for amyloid clearance and drug delivery. Stem Cell Reports  2020; 14(5): 924-39.
[http://dx.doi.org/10.1016/j.stemcr.2020.03.011] [PMID:  32275861] 
[74] 
Yasuda M, Maeda S, Kawamata T, et al. Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry  2000; 68(2): 220-3.
[http://dx.doi.org/10.1136/jnnp.68.2.220] [PMID:  10644793] 
[75] 
Chelban V, Breza M, Szaruga M, et al. Spastic paraplegia preceding PSEN1-related familial Alzheimer’s disease. Alzheimers Dement (Amst)  2021; 13(1): e12186.
[http://dx.doi.org/10.1002/dad2.12186] [PMID:  33969176] 
[76] 
Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol  2019; 15(10): 565-81.
[http://dx.doi.org/10.1038/s41582-019-0244-7] [PMID:  31501588] 
[77] 
Koriath CAM, Kenny J, Ryan NS, et al. Genetic testing in dementia - utility and clinical strategies. Nat Rev Neurol  2021; 17(1): 23-36.
[http://dx.doi.org/10.1038/s41582-020-00416-1] [PMID:  33168964] 
[78] 
Tariot PN, Lopera F, Langbaum JB, et al. Alzheimer’s Prevention Initiative. The Alzheimer’s Prevention initiative autosomal-dominant Alzheimer’s disease trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y)  2018; 4(1): 150-60.
[http://dx.doi.org/10.1016/j.trci.2018.02.002] [PMID:  29955659] 
[79] 
Wang G, Zhang DF, Jiang HY, et al. Mutation and association analyses of dementia-causal genes in Han Chinese patients with early-onset and familial Alzheimer’s disease. J Psychiatr Res  2019; 113: 141-7.
[http://dx.doi.org/10.1016/j.jpsychires.2019.03.026] [PMID:  30954774] 
[80] 
Hanafy AS, Schoch S, Lamprecht A. CRISPR/Cas9 Delivery potentials in Alzheimer’s Disease management: A mini review. Pharmaceutics  2020; 12(9): E801.
[http://dx.doi.org/10.3390/pharmaceutics12090801] [PMID:  32854251] 
[81] 
Hutton M, Busfield F, Wragg M, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer’s disease. Neuroreport  1996; 7(3): 801-5.
[http://dx.doi.org/10.1097/00001756-199602290-00029] [PMID:  8733749] 
[82] 
Prihar G, Verkkoniem A, Perez-Tur J, et al. Alzheimer disease PS-1 exon 9 deletion defined. Nat Med  1999; 5(10): 1090.
[http://dx.doi.org/10.1038/13383] [PMID:  10502791] 
[83] 
Hooli BV, Kovacs-Vajna ZM, Mullin K, et al. Rare autosomal copy number variations in early-onset familial Alzheimer’s disease. Mol Psychiatry  2014; 19(6): 676-81.
[http://dx.doi.org/10.1038/mp.2013.77] [PMID:  23752245] 
[84] 
Hsu S, Gordon BA, Hornbeck R, et al. Dominantly Inherited Alzheimer Network (DIAN). Discovery and validation of autosomal dominant Alzheimer’s disease mutations. Alzheimers Res Ther  2018; 10(1): 67.
[http://dx.doi.org/10.1186/s13195-018-0392-9] [PMID:  30021643] 
[85] 
Ataka S, Tomiyama T, Takuma H, et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol  2004; 61(11): 1773-6.
[http://dx.doi.org/10.1001/archneur.61.11.1773] [PMID:  15534188] 
[86] 
Murayama O, Tomita T, Nihonmatsu N, et al. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer’s disease. Neurosci Lett  1999; 265(1): 61-3.
[http://dx.doi.org/10.1016/S0304-3940(99)00187-1] [PMID:  10327206] 
[87] 
Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y. Recognition of the amyloid precursor protein by human γ-secretase. Science  2019; 363(6428): eaaw0930.
[http://dx.doi.org/10.1126/science.aaw0930] [PMID:  30630874] 
[88] 
Moehlmann T, Winkler E, Xia X, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA  2002; 99(12): 8025-30.
[http://dx.doi.org/10.1073/pnas.112686799] [PMID:  12048239] 
[89] 
Sannerud R, Esselens C, Ejsmont P, et al. Restricted location of PSEN2/γ-secretase determines substrate specificity and generates an intracellular aβ pool. Cell  2016; 166(1): 193-208.
[http://dx.doi.org/10.1016/j.cell.2016.05.020] [PMID:  27293189] 
[90] 
Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci USA  2017; 114(4): E476-85.
[http://dx.doi.org/10.1073/pnas.1618657114] [PMID:  27930341] 
[91] 
Bai XC, Yan C, Yang G, et al. An atomic structure of human γ-secretase. Nature  2015; 525(7568): 212-7.
[http://dx.doi.org/10.1038/nature14892] [PMID:  26280335] 
[92] 
Jiménez Caballero PE, Lladó A, de Diego Boguna C, Martin Correa E, Serviá Candela M, Marsal Alonso C. A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer’s disease and spastic paraparesis. Eur J Neurol  2008; 15(9): 991-4.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02230.x] [PMID:  18637955] 
[93] 
Campion D, Flaman JM, Brice A, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer’s disease. Hum Mol Genet  1995; 4(12): 2373-7.
[http://dx.doi.org/10.1093/hmg/4.12.2373] [PMID:  8634712] 
[94] 
Marrosu MG, Floris G, Costa G, et al. Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation. Neurology  2006; 66(1): 108-11.
[http://dx.doi.org/10.1212/01.wnl.0000191360.08881.12] [PMID:  16401857] 
[95] 
Ikeuchi T, Kaneko H, Miyashita A, et al. Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement Geriatr Cogn Disord  2008; 26(1): 43-9.
[http://dx.doi.org/10.1159/000141483] [PMID:  18587238] 
[96] 
Ringman JMDN, Signer R, Martinez-Agosto J, et al. P1-123: Very young onset autosomal dominant Alzheimer’s disease with spastic paraparesis due to a novel (F388S) PSEN1 mutation (poster abstract). Alzheimers Dement  2019; 15: P282.
[http://dx.doi.org/10.1016/j.jalz.2019.06.678] 
[97] 
Beck JA, Poulter M, Campbell TA, et al. Somatic and germline mosaicism in sporadic early-onset Alzheimer’s disease. Hum Mol Genet  2004; 13(12): 1219-24.
[http://dx.doi.org/10.1093/hmg/ddh134] [PMID:  15115757] 
[98] 
Taddei K, Kwok JB, Kril JJ, et al. Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer’s disease. Neuroreport  1998; 9(14): 3335-9.
[http://dx.doi.org/10.1097/00001756-199810050-00034] [PMID:  9831473] 

Rights & Permissions Print Cite

Article Metrics

29

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1567205019666220414101251	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828

Current Alzheimer Research

Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis

Abstract Play Pause

Related Journals

Related Books

Abstract